ISG/AIEOP EW-1: Randomised controlled trial for patients with non-metastatic Ewing sarcoma
Phase 3
Completed
- Conditions
- on-metastatic Ewing sarcomaCancerBenign neoplasm of bone and articular cartilage
- Registration Number
- ISRCTN50580483
- Lead Sponsor
- Italian Sarcoma Group (Italy)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 220
Inclusion Criteria
1. Patients with non-metastatic Ewing sarcoma
2. Aged less than 41 years, either sex
3. No previous treatment for the disease
4. Informed consent
Exclusion Criteria
1. Metastatic Ewing sarcoma
2. Medical contraindications to the protocol drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival, measured at four years
- Secondary Outcome Measures
Name Time Method 1. Event-free survival,measured at four years<br>2. Percent of patients with good response to primary chemotherapy<br>3. Received dose/intensity<br>4. Chemotherapy toxicity